Azathioprine for multiple sclerosis (Q24242945)

title

Azathioprine for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

12 May 2020

0 references

0 references

3

0 references

author name string

I Casetta

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

12 May 2020

G Iuliano

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

12 May 2020

G Filippini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

Cochrane Database of Systematic Reviews

12 May 2020

publication date

17 October 2007

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

12 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

12 May 2020

page(s)

CD003982

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

12 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

The efficacy of azathioprine in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Effectiveness of azathioprine treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Azathioprine in treatment of multiple sclerosis. Final results of a 41/2-year controlled study of its effectiveness covering 115 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Azathioprine in multiple sclerosis--a 3 year controlled study of its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Prolonged azathioprine treatment of non-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Multiple sclerosis unaffected by azathioprine in pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Long-term treatment of multiple sclerosis with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Long-term safety of azathioprine therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Guidelines for prescribing azathioprine in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Azathioprine in dermatology: the past, the present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Azathioprine-associated myelodysplastic syndrome with cytogenetic aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003982.PUB2

New treatments and azathioprine in multiple sclerosis

21 January 2018

1 reference

12 December 2020

Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report

1 reference

12 December 2020

A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis

1 reference

12 December 2020

[Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience]

1 reference

12 December 2020

A double blind study on azathioprine efficacy in multiple sclerosis: final report

1 reference

12 December 2020

The risk of cancer from azathioprine as a treatment for multiple sclerosis

1 reference

12 December 2020

The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine

1 reference

12 December 2020

Clinical and hematologic study of 6[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W.57-322) and related compounds

1 reference

12 December 2020

Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7

1 reference

12 December 2020

Therapeutic trial of Imuran (azathioprine) in multiple sclerosis

1 reference

12 December 2020

Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis

1 reference

12 December 2020

Oncogenicity of immunosuppressive drugs

1 reference

12 December 2020

Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis

1 reference

12 December 2020

Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging

1 reference

12 December 2020

Double-blind, controlled trial of immunosuppression in treatment of multiple sclerosis

1 reference

12 December 2020

Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group

1 reference

12 December 2020

[Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982]

1 reference

12 December 2020

10.1002/14651858.CD003982.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3448093

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

OpenCitations bibliographic resource ID

12 May 2020

3448093

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6823213&resulttype=core&format=json

12 May 2020

PubMed publication ID

17943809

1 reference